Low cost and just in time inventory have been the manufacturing mantra for automobiles, iPhones, healthcare technology, and Christmas toys. COVID-19 brought the balance of cost and risk in the supply chain into sharp focus for the pharmaceutical, medical device, and medical technology sectors of the US economy.
Non-US manufacturers and suppliers are an essential component of the current healthcare technology system serving US and European markets. About 80% of products and ingredients used in US pharmaceuticals come from China and other non-US manufacturers. Challenges and likely changes to these supply chains are the topics of this program.
Learn how the CEOs of pharmaceutical and medical technology companies in the US and China are adapting to this changing and uncertain world trading environment. Prof. Willy Shih from Harvard Business School will also share his perspective on the outlook for supply chains serving US and global medical and pharma manufacturers.